Abstract
Azithromycin, a recently introduced antibiotic, offers the potential advantages of short-course administration and lower toxicity compared to other macrolides. Approved for the treatment of mild pneumonia, this drug was investigated in a study of patients hospitalized for community-acquired pneumonia. In an open-labelled randomized study, oral azithromycin was compared with intravenous benzylpenicillin in patients suspected to have pneumonococcal pneumonia. Azithromycin was also compared with erythromycin, both administered orally, in all other patients. Three hundred thirty-four patients with community-acquired pneumonia were hospitalized, 108 of whom were randomized; 104 could be evaluated. A need for intravenous therapy was the most common reason for exclusion. In the pneumococcal group, 35 patients received azithromycin and 29 benzylpenicillin. The clinical and radiological success rate achieved with azithromycin (83 %) was considerably higher than that achieved with benzylpenicillin (66 %), though the difference was not significant. In the non-pneumococcal group, 19 patients received azithromycin and 21 erythromycin; no differences in the success rate were found (79 % and 76 %, respectively). Eight patients on azithromycin had a blood culture positive forStreptococcus pneumoniae; in three of these patients therapy was changed. None of the five patients with pneumococcal bacteraemia who received benzylpenicillin required a change in therapy. It is concluded that oral azithromycin, administered as short-course therapy, is an appropriate antibiotic for treating patients with community-acquired pneumonia. However, it is not yet certain that azithromycin is a good choice for patients with pneumococcal bacteraemia.
Similar content being viewed by others
References
Garibaldi RA: Epidemiology of community-acquired respiratory tract infections in adults. American Journal of Medicine 1985, 78, Supplement 6B: 32–37.
Macfarlane JT: Community-acquired pneumonia. British Journal of Diseases of Chest 1987, 81: 116–127.
Macfarlane JT: Recent advances in respiratory medicine. Churchill Livingstone, Edinburgh, 1991, p. 109–124.
Fang G, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston TJ, Wang SP, Kohler R, Muder RR, Yee YC, Rihs JD, Vickers RM: New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990, 69: 307–316.
Pennington JE: Respiratory infections: diagnosis and management. Raven Press, New York, 1988, p. 159–171.
Musher DM: Infections caused byStreptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clinical Infectious Diseases 1992, 14: 801–809.
Research Committee of the British Thoracic Society: Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. British Journal of Hospital Medicine 1993, 49: 346–350.
Ball P: The future role and importance of macrolides. Journal of Hospital Infection 1991, 19, Supplement A: 47–59.
Bahal N, Nahata MC: The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Annals of Pharmacotherapy 1992, 26: 46–55.
Peters DH, Friedel HA, McTavish D: Focus on azithromycin. Drugs 1992, 44: 750–799.
Neu HC: Clinical microbiology of azithromycin. American Journal of Medicine 1991, 91, Supplement 3A: 12–18.
Schentag JJ, Ballow CH: Tissue-directed pharmacokinetics. American Journal of Medicine 1991, 91, Supplement 3A: 5–11.
Coonrod DJ: Pneumococcal pneumonia. Seminars in Respiratory Infections 1989, 4: 4–11.
Kuikka A, Syrjanen J, Renkonen O, Valtonen VV: Pneumococcal bacteraemia during a recent decade. Scandinavian Journal of Infectious Diseases 1992, 24: 157–168.
Örtqvist A, Kalin M, Julander I, Mufson MA: Deaths in bacteremic pneumococcal pneumonia: a comparison of two populations in Huntington, West Virginia, and Stockholm, Sweden. Chest 1993, 103: 710–716.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bohte, R., van't Wout, J.W., Lobatto, S. et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 14, 182–187 (1995). https://doi.org/10.1007/BF02310353
Issue Date:
DOI: https://doi.org/10.1007/BF02310353